Quantamental Technologies LLC Invests $43,000 in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Quantamental Technologies LLC acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,389 shares of the biotechnology company’s stock, valued at approximately $43,000.

Other institutional investors have also recently modified their holdings of the company. Bank of Montreal Can grew its position in shares of BioCryst Pharmaceuticals by 921.9% in the 2nd quarter. Bank of Montreal Can now owns 10,219 shares of the biotechnology company’s stock worth $39,000 after buying an additional 9,219 shares during the last quarter. Summit Securities Group LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $132,000. SG Americas Securities LLC purchased a new position in shares of BioCryst Pharmaceuticals in the 1st quarter worth approximately $169,000. BNP Paribas Arbitrage SA grew its position in shares of BioCryst Pharmaceuticals by 61,281.1% in the 1st quarter. BNP Paribas Arbitrage SA now owns 22,711 shares of the biotechnology company’s stock worth $185,000 after buying an additional 22,674 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale grew its position in shares of BioCryst Pharmaceuticals by 22.2% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 38,500 shares of the biotechnology company’s stock worth $276,000 after buying an additional 7,000 shares during the last quarter. 90.74% of the stock is currently owned by hedge funds and other institutional investors.

NASDAQ BCRX traded down $0.07 on Friday, hitting $3.08. 771,748 shares of the company’s stock traded hands, compared to its average volume of 1,312,328. The company has a debt-to-equity ratio of 2.38, a quick ratio of 1.43 and a current ratio of 1.44. BioCryst Pharmaceuticals, Inc. has a 1-year low of $2.49 and a 1-year high of $9.95. The firm’s 50-day moving average price is $2.91 and its two-hundred day moving average price is $5.30.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.03). BioCryst Pharmaceuticals had a negative net margin of 1,091.44% and a negative return on equity of 371.33%. The business had revenue of $1.45 million for the quarter, compared to analyst estimates of $2.52 million. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.23 earnings per share for the current year.

A number of research analysts have recently issued reports on the stock. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, August 28th. Jefferies Financial Group dropped their target price on shares of BioCryst Pharmaceuticals from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, May 22nd. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 8th. HC Wainwright reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Wednesday, May 22nd. Finally, JMP Securities dropped their target price on shares of BioCryst Pharmaceuticals from $18.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, May 23rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $9.08.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

See Also: What does a neutral rating on stocks mean?

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.